(taken directly from the application) The broad objective of this proposal is to assess the effects of sustained reductions in arterial pressure on the progression of renal disease in African-Americans.
The specific aims of this proposal are to assess whether the level of blood pressure reduction affects the progression of renal disease in African-American patients with pre- existing hypertensive renal disease. Hypothesis: Reductions in mean arterial pressure (MAP) to less than 92 mmHg will slow progression of renal disease to a greater extent than higher pressures. 2) To assess whether the class of antihypertensive agent used to achieve a certain level of blood pressure reduction has an effect on preserving renal function independent of arterial pressure reduction. Hypothesis: Certain classes of antihypertensive agents such as converting enzyme inhibitors will slow progression of renal disease independent of their effects on blood pressure reduction. The design of the trial is randomized, prospective, double blind, double dummy. The study population sought is African-Americans with varying degrees of renal insufficiency and modest amounts of proteinuria. One third of these subjects should be female. After screening and randomization to a given class of antihypertensive medications and goal MAP level, subjects will have follow-up every three months, over at least a four year period not to exceed six years. These three month visits will include measurements of glomerular filtration rate, 24 hour urine for protein, urea and electrolytes, blood chemistries and complete blood counts. Hopefully this study will provide data that will subsequently enable physicians to optimize the management and care of African-Americans with hypertension. This will ideally lead to a slowed progression of renal disease in this high risk population and should ultimately reduce morbidity from end stage renal disease and dialysis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DK048643-02
Application #
2149037
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1994-08-15
Project End
2001-06-30
Budget Start
1995-08-01
Budget End
1996-06-30
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Rush University Medical Center
Department
Type
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
60612
Norman, Silas P; Kommareddi, Mallika; Ojo, Akinlolu O et al. (2011) Early pancreas graft failure is associated with inferior late clinical outcomes after simultaneous kidney-pancreas transplantation. Transplantation 92:796-801
Weinberg, Joy M; Appel, Lawrence J; Bakris, George et al. (2009) Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 169:1587-94
Gassman, Jennifer J; Greene, Tom; Wright Jr, Jackson T et al. (2003) Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol 14:S154-65
Wright Jr, Jackson T; Bakris, George; Greene, Tom et al. (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288:2421-31
Kusek, John W; Greene, Paul; Wang, Shin-Ru et al. (2002) Cross-sectional study of health-related quality of life in African Americans with chronic renal insufficiency: the African American Study of Kidney Disease and Hypertension Trial. Am J Kidney Dis 39:513-24